Comparison of the Prevalence of Psychiatric Disorders in Performance-Enhancing Drug Users and Nonuser Bodybuilders
Objective: The present study aimed at comparing the prevalence of major psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, and generalized anxiety disorder between performance-enhancing drug users and nonuser bodybuilders. Moreover, the prevalence of major psychiatric disorders in bodybuilders was also reported.
Method: In this study, 453 athletes were recruited from Bushehr bodybuilding gyms from February to May 2015. A structured questionnaire was used to collect the participants’ information, including demographic characteristics, sports’ status and performance-enhancing drug use. According to the condition of performance-enhancing drug use, the participants were divided into current users, non-current users, and nonusers. The psychiatric status of the participants was evaluated using DSM-IV diagnostic criteria for major depressive disorder, bipolar disorder, generalized anxiety disorder, and schizophrenia. We also asked about the acute psychotic disturbances after using performance-enhancing drugs, alcohol use, and history of aggressive behavior in bodybuilders. Data were analyzed using one-way analysis of variance and chi-square tests.
Results: Prevalence of major depressive disorder, bipolar disorder, schizophrenia, generalized anxiety disorder, and the overall prevalence of psychiatric disorders in the bodybuilders was 19.7%, 3.8%, 1.5%, 16.6%, and 26.7%, respectively. After using performance-enhancing drugs, 33% of the bodybuilders had experienced acute psychological disturbances. There were no significant differences between current, non-current, and nonuser bodybuilding athletes in the measured psychiatric disorders.
Conclusion: Prevalence of psychiatric disorders was not significantly different in performance-enhancing drug users and nonusers. Thus, it can be concluded that performance-enhancing drugs do not increase the risk of psychiatric disorders in bodybuilders.
Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic‐androgenic steroid use and dependence in Americans: Current best estimates. Am J Addict 2014; 23: 371-377.
Kanayama G, Hudson JI, Pope HG. Illicit anabolic–androgenic steroid use. Horm Behav 2010; 58: 111-121.
Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34: 513-554.
Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes: a constant threat. Toxicol Lett 2005; 168: 167-175.
Pope H, Katz D. Psychiatric effects of exogenous anabolic-androgenic steroids. Psychoneuroendocrinology: The scientific basis of clinical practice. Washington, DC: American Psychiatric Press; 2003.
van Amsterdam J, Hartgens F. Acute and chronic adverse reaction of anabolic–androgenic steroids. Adverse Drug React Bull 2014; 288: 1111-1114.
Perry PJ, Kutscher EC, Lund BC, Yates WR, Holman TL, Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci 2003; 48: 646-651.
Lukas SE. CNS effects and abuse liability of anabolic-androgenic steroids. Annu Rev Pharmacol Toxicol 1996; 36: 333-357
Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry 1999; 11: 223-231.
Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic–androgenic steroid abuse: A looming public health concern? Drug Alcohol Depend 2008; 98: 1-12.
Daly RC1, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology 2003; 28: 317-331.
Clark AS, Henderson LP. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci Biobehav Rev 2003; 27: 413-436.
Dodge T, Hoagland MF. The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend 2011; 114: 100-109.
Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The Anabolic 500 Survey: Characteristics of Male Users versus Nonusers of Anabolic-Androgenic Steroids for Strength Training Pharmacother 2011; 31: 757-766.
Markser VZ. Sport psychiatry and psychotherapy. Mental strains and disorders in professional sports. Challenge and answer to societal changes. Eur Arch Psychiatry Clin Neurosci 2011; Suppl 2: S182-185.
Noorbala AA, Bagheri Yazdi SA, Yasamy MT, Mohammad K. Mental health survey of the adult population in Iran. Br J Psychiatry 2004; 184: 70-73.
Mangweth B, Pope HG Jr, Kemmler G, Ebenbichler C, Hausmann A, De Col C, et al. Body image and psychopathology in male bodybuilders. Psychother Psychosom 2001; 70: 38-43.
Sanjuan PM, Langenbucher JL, Hildebrandt T. Mood symptoms in steroid users: the unexamined role of concurrent stimulant use. J Subst Use 2016; 21: 395-399.
Casavant MJ, Blake K, Griffith J, Yates A, Copley LM. Consequences of use of anabolic androgenic steroids. Pediatr Clin North Am 2007; 54: 677-690.
Angoorani H, Halabchi F. The Misuse of Anabolic-Androgenic Steroids among Iranian Recreational Male Body-Builders and Their Related Psycho-Socio-Demographic factors. Iran J Public Health 2015; 44: 1662-1669.
Lindqvist A, Eriksson B, Ehrnborg C, Fahlke C, Moberg T, Rosén T, eds. AAS abuse in former competitive sport athletes. First Nordic conference on abuse of anabolic steroids and anti-doping work; 2007.
Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996; 153: 974-984.
Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, et al. The Effects of Pharmacologically Induced Hypogonadism on Mood in HealthyMen. Arch Gen Psychiatry 2004; 61: 997-1004.
Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997; 44: 87-94.
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2013; 35: 341-375.
Choi PY, Pope HG Jr. Violence toward women and illicit androgenic-anabolic steroid use. Ann Clin Psychiatry 1994; 6: 21-25.
Oberlander JG, Henderson LP. The Sturm und Drang of anabolic steroid use: angst, anxiety, and aggression. Trends Neurosci 2012; 35: 382-392.
Rejeski WJ, Brubaker PH, Herb RA, Kaplan JR, Koritnik D. Anabolic steroids and aggressive behavior in cynomolgus monkeys. J Behav Med 1988; 11: 95-105.
Johansson P, Lindqvist A, Nyberg F, Fahlke C. Anabolic androgenic steroids affects alcohol intake, defensive behaviors and brain opioid peptides in the rat. Pharmacol Biochem Behav 2000; 67: 271-279.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.